Analisi facoltativa del prodotto
Con il tuo consenso utilizziamo analisi limitate e rispettose della privacy per capire quali percorsi di ricerca funzionano. Non usiamo tracker pubblicitari né registrazioni delle sessioni. Puoi modificare questa scelta nelle Preferenze. Leggi la Informativa sulla privacy.
Teleflex Incorporated's published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $5.5B | |
|---|---|---|
| Revenue (ttm) | 2.3B | |
| Net income (ttm) | -1B | |
| EPS (ttm) | -$23.4 | |
| Shares out | 42.4M | |
| P/E (forward) | 11.0x | |
| Dividend | $1.36 (0.98%) | |
| Volume | 501,819 | |
| Beta | 0.83 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $2.81B | $2.79B | $1.71B | $1.70B | $1.99B | -8.2% |
| Gross profit | $1.55B | $1.53B | $1.04B | $1.04B | $1.12B | -7.8% |
| Operating income | $628.1M | $499.7M | $258.7M | $103.7M | $118.4M | -34.1% |
| Net income | $485.4M | $363.1M | $356.3M | $69.7M | $-905.6M | — |
| EPS (diluted) | $10.23 | $7.68 | $7.53 | $1.48 | $-20.25 | — |
| EBITDA | $853.8M | $730.8M | $761.2M | $433.6M | $302.5M | -22.8% |
| R&D | $130.8M | $153.8M | $113.6M | $109.0M | $144.8M | +2.6% |
| SG&A | $860.1M | $863.7M | $622.7M | $674.5M | $720.2M | -4.3% |
Recent company headlines from major financial publishers.
Teleflex delivers on its stated restructuring objectives, stabilizing Interventional growth while Vascular and Surgical maintain steady procedural gains. Operating margins expand from guided 19.0% in FY2026 to 21.0% in FY2027 and 23.0% by FY2030 as transition service agreements offset separation friction and restructuring generates $50M in pre-tax savings. Debt paydown of $800M and $1.0B in cumulative share repurchases support consensus FY2027 EPS of $10.95, yielding a mid-case fair value of $122.83.
Biotronik integration bottlenecks resolve rapidly by year-end 2026, allowing Interventional to re-accelerate alongside Vascular (8.0% Q2 growth) and Surgical (9.2% Q2 growth) franchises. Transition services and restructuring programs eliminate all stranded corporate costs, expanding operating margin to 24.5%. Proceeds from all three divestitures fund the complete $1.0B repurchase and $800M debt reduction, driving adjusted EPS past consensus and supporting a bull-case valuation of $190.97.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 7.9% | $134 | $137 | $141 | $145 | $149 |
| 8.4% | $125 | $128 | $131 | $134 | $138 |
| 8.9% | $118 | $120 | $123 | $126 | $129 |
| 9.4% | $111 | $113 | $116 | $118 | $120 |
| 9.9% | $105 | $107 | $109 | $111 | $113 |
Upcoming earnings date and setup when available.
Il rating riportato dall'edizione di ricerca pubblicata ogni mese. Un rating confronta il prezzo alla data dell'analisi con il valore equo; non indica se la valutazione si è rivelata corretta.
| Anno | gen | feb | mar | apr | mag | giu | lug | ago | set | ott | nov | dic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |